We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Blood Test Predicts Cognitive Decline in Alzheimer's Patients

By LabMedica International staff writers
Posted on 23 Jun 2025

Rapid progression in Alzheimer’s disease (AD) is difficult to predict, especially during the mild cognitive impairment (MCI) stage, when patient outcomes vary widely. More...

While insulin resistance is known to contribute to the development of AD, its impact on how quickly cognitive decline progresses has been underexplored. Now, a new study presented at the European Academy of Neurology (EAN) Congress 2025 shows that insulin resistance, measured by a routine triglyceride-glucose (TyG) index, can identify early-stage Alzheimer’s patients who are four times more likely to experience rapid cognitive deterioration.

This study by neurologists at the University of Brescia (Brescia, Italy) focused on understanding whether insulin resistance could serve as a predictive marker for disease progression in people with early AD. Their focus was on the prodromal MCI stage, where clinical trajectories can differ significantly. The researchers used the TyG index—a low-cost and widely available surrogate for insulin resistance—to assess metabolic dysfunction in 315 non-diabetic patients with cognitive deficits. Among these, 200 had biologically confirmed AD. Each participant underwent TyG assessment and a three-year clinical follow-up to monitor cognitive outcomes.

The study's findings revealed that in the MCI-AD subgroup, patients in the highest third of TyG index values showed markedly faster cognitive decline, losing more than 2.5 points per year on the Mini Mental State Examination. This group had a hazard ratio of 4.08 (95% CI 1.06–15.73) for rapid decline compared to those with lower TyG scores. No similar association was found in patients with non-AD neurodegenerative conditions, indicating a disease-specific sensitivity to metabolic dysfunction in Alzheimer’s.

Further analysis showed that high TyG levels were also associated with blood–brain barrier disruption and cardiovascular risk factors. However, there was no interaction with the APOE ε4 genotype, suggesting that genetic and metabolic risk factors may influence AD progression through separate pathways. In practical terms, the TyG index could help clinicians identify high-risk patients early in the disease course, offering an opportunity to tailor interventions that improve insulin sensitivity. It also holds promise for refining patient selection in anti-amyloid or anti-tau clinical trials. The team is now exploring how TyG correlates with neuroimaging biomarkers to aid in early detection and patient stratification.

“Once mild cognitive impairment is diagnosed, families always ask how fast it will progress”, said lead investigator Dr. Bianca Gumina. “Our data show that a simple metabolic marker available in every hospital laboratory can help identify more vulnerable subjects who may be suitable candidates for targeted therapy or specific intervention strategies.”

Related Links:
University of Brescia


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.